258 related articles for article (PubMed ID: 19800577)
41. MEK1 is required for the development of NRAS-driven leukemia.
Nowacka JD; Baumgartner C; Pelorosso C; Roth M; Zuber J; Baccarini M
Oncotarget; 2016 Dec; 7(49):80113-80130. PubMed ID: 27741509
[TBL] [Abstract][Full Text] [Related]
42. In vivo RNAi screening identifies regulators of actin dynamics as key determinants of lymphoma progression.
Meacham CE; Ho EE; Dubrovsky E; Gertler FB; Hemann MT
Nat Genet; 2009 Oct; 41(10):1133-7. PubMed ID: 19783987
[TBL] [Abstract][Full Text] [Related]
43. An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer.
Zender L; Xue W; Zuber J; Semighini CP; Krasnitz A; Ma B; Zender P; Kubicka S; Luk JM; Schirmacher P; McCombie WR; Wigler M; Hicks J; Hannon GJ; Powers S; Lowe SW
Cell; 2008 Nov; 135(5):852-64. PubMed ID: 19012953
[TBL] [Abstract][Full Text] [Related]
44. Forward RNAi Screens in Human Hematopoietic Stem Cells.
Galeev R; Karlsson C; Baudet A; Larsson J
Methods Mol Biol; 2017; 1622():29-50. PubMed ID: 28674799
[TBL] [Abstract][Full Text] [Related]
45. Induction of ectopic Myc target gene JAG2 augments hypoxic growth and tumorigenesis in a human B-cell model.
Yustein JT; Liu YC; Gao P; Jie C; Le A; Vuica-Ross M; Chng WJ; Eberhart CG; Bergsagel PL; Dang CV
Proc Natl Acad Sci U S A; 2010 Feb; 107(8):3534-9. PubMed ID: 20133585
[TBL] [Abstract][Full Text] [Related]
46. Combined loss of PUMA and p21 accelerates c-MYC-driven lymphoma development considerably less than loss of one allele of p53.
Valente LJ; Grabow S; Vandenberg CJ; Strasser A; Janic A
Oncogene; 2016 Jul; 35(29):3866-71. PubMed ID: 26640149
[TBL] [Abstract][Full Text] [Related]
47. Therapeutic Response to Non-genotoxic Activation of p53 by Nutlin3a Is Driven by PUMA-Mediated Apoptosis in Lymphoma Cells.
Valente LJ; Aubrey BJ; Herold MJ; Kelly GL; Happo L; Scott CL; Newbold A; Johnstone RW; Huang DC; Vassilev LT; Strasser A
Cell Rep; 2016 Mar; 14(8):1858-66. PubMed ID: 26904937
[TBL] [Abstract][Full Text] [Related]
48. p53 and p73 in suppression of Myc-driven lymphomagenesis.
Griesmann H; Schlereth K; Krause M; Samans B; Stiewe T
Int J Cancer; 2009 Jan; 124(2):502-6. PubMed ID: 18942718
[TBL] [Abstract][Full Text] [Related]
49. Modulation of the angiogenesis response through Ha-ras control, placenta growth factor, and angiopoietin expression in mouse skin carcinogenesis.
Larcher F; Franco M; Bolontrade M; Rodriguez-Puebla M; Casanova L; Navarro M; Yancopoulos G; Jorcano JL; Conti CJ
Mol Carcinog; 2003 Jun; 37(2):83-90. PubMed ID: 12766907
[TBL] [Abstract][Full Text] [Related]
50. Expression of cyclin-dependent kinase subunit 1 (Cks1) is regulated during the cell cycle by a CDE/CHR tandem element and is downregulated by p53 but not by p63 or p73.
Rother K; Li YY; Tschöp K; Kirschner R; Müller GA; Mössner J; Engeland K
Cell Cycle; 2007 Apr; 6(7):853-62. PubMed ID: 17377499
[TBL] [Abstract][Full Text] [Related]
51. A genetic screen for candidate tumor suppressors identifies REST.
Westbrook TF; Martin ES; Schlabach MR; Leng Y; Liang AC; Feng B; Zhao JJ; Roberts TM; Mandel G; Hannon GJ; Depinho RA; Chin L; Elledge SJ
Cell; 2005 Jun; 121(6):837-48. PubMed ID: 15960972
[TBL] [Abstract][Full Text] [Related]
52. Tumorigenic activity and therapeutic inhibition of Rheb GTPase.
Mavrakis KJ; Zhu H; Silva RL; Mills JR; Teruya-Feldstein J; Lowe SW; Tam W; Pelletier J; Wendel HG
Genes Dev; 2008 Aug; 22(16):2178-88. PubMed ID: 18708578
[TBL] [Abstract][Full Text] [Related]
53. ISL2 modulates angiogenesis through transcriptional regulation of ANGPT2 to promote cell proliferation and malignant transformation in oligodendroglioma.
Qi L; Wang ZY; Shao XR; Li M; Chen SN; Liu XQ; Yan S; Zhang B; Zhang XD; Li X; Zhao W; Pan JA; Zhao B; Zhang XD
Oncogene; 2020 Sep; 39(37):5964-5978. PubMed ID: 32753650
[TBL] [Abstract][Full Text] [Related]
54. Genome-wide analysis of p53-regulated transcription in Myc-driven lymphomas.
Tonelli C; Morelli MJ; Sabò A; Verrecchia A; Rotta L; Capra T; Bianchi S; Campaner S; Amati B
Oncogene; 2017 May; 36(21):2921-2929. PubMed ID: 28092679
[TBL] [Abstract][Full Text] [Related]
55. Loss of p73 promotes dissemination of Myc-induced B cell lymphomas in mice.
Nemajerova A; Petrenko O; Trümper L; Palacios G; Moll UM
J Clin Invest; 2010 Jun; 120(6):2070-80. PubMed ID: 20484818
[TBL] [Abstract][Full Text] [Related]
56. p53 deficiency increases transformation by v-Abl and rescues the ability of a C-terminally truncated v-Abl mutant to induce pre-B lymphoma in vivo.
Zou X; Cong F; Coutts M; Cattoretti G; Goff SP; Calame K
Mol Cell Biol; 2000 Jan; 20(2):628-33. PubMed ID: 10611241
[TBL] [Abstract][Full Text] [Related]
57. Early growth response 1 acts as a tumor suppressor in vivo and in vitro via regulation of p53.
Krones-Herzig A; Mittal S; Yule K; Liang H; English C; Urcis R; Soni T; Adamson ED; Mercola D
Cancer Res; 2005 Jun; 65(12):5133-43. PubMed ID: 15958557
[TBL] [Abstract][Full Text] [Related]
58. FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis.
Paik JH; Kollipara R; Chu G; Ji H; Xiao Y; Ding Z; Miao L; Tothova Z; Horner JW; Carrasco DR; Jiang S; Gilliland DG; Chin L; Wong WH; Castrillon DH; DePinho RA
Cell; 2007 Jan; 128(2):309-23. PubMed ID: 17254969
[TBL] [Abstract][Full Text] [Related]
59. Apaf-1 and caspase-9 do not act as tumor suppressors in myc-induced lymphomagenesis or mouse embryo fibroblast transformation.
Scott CL; Schuler M; Marsden VS; Egle A; Pellegrini M; Nesic D; Gerondakis S; Nutt SL; Green DR; Strasser A
J Cell Biol; 2004 Jan; 164(1):89-96. PubMed ID: 14709542
[TBL] [Abstract][Full Text] [Related]
60. A systematic search for downstream mediators of tumor suppressor function of p53 reveals a major role of BTG2 in suppression of Ras-induced transformation.
Boiko AD; Porteous S; Razorenova OV; Krivokrysenko VI; Williams BR; Gudkov AV
Genes Dev; 2006 Jan; 20(2):236-52. PubMed ID: 16418486
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
